Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer
NCT02934984 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2019-04-17
Summary
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA(ctDNA) can help early screening of pancreatic cancer recurrence or not. And we are also planning to evaluate correlation between ctDNA with clinical outcome of pancreatic cancer.
Conditions
Sponsors & Collaborators
-
Samsung Medical Center
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2020-07-31
- Completion
- 2021-01-31
Countries
- South Korea
Study Locations
More Related Trials
-
Early Detection of Pancreatic Cancer
NCT05596435 ·Status: UNKNOWN
-
Biomarkers in Predicting Response to Treatment in Patients Who Have Undergone Surgery for Pancreatic Cancer
NCT00897832 ·Status: COMPLETED
-
Cancer Stem Cell Specific Aptamer's Ability to Detect Blood Circulating Cancer Stem Cells and Its Role as a Predictor of Prognosis in Pancreatic Cancer
NCT05745415 ·Status: COMPLETED
-
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
NCT04281511 ·Status: COMPLETED
-
Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy
NCT07122466 ·Status: ACTIVE_NOT_RECRUITING
-
GUIDING MULTI-MODAL THERAPIES AGAINST MINIMAL RESIDUAL DISEASE BY LIQUID BIOPSIES
NCT06102889 ·Status: ENROLLING_BY_INVITATION
-
ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
NCT05479708 ·Status: ACTIVE_NOT_RECRUITING
-
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT05802394 ·Status: RECRUITING ·Phase: NA
-
Predicting Effective Therapy in Pancreatic Cancer
NCT03033927 ·Status: ACTIVE_NOT_RECRUITING
-
New Predictive Marker for Pancreatic Cancer Using CA19-9 and Fecal Elastase
NCT05923567 ·Status: ACTIVE_NOT_RECRUITING
-
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis
NCT02869802 ·Status: RECRUITING
-
Biomarkers Study in Pancreatic Cancer
NCT01666184 ·Status: UNKNOWN
-
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
NCT03435536 ·Status: COMPLETED ·Phase: NA
-
Early Diagnosis of Pancreatic Cancer Duodenal Fluid-Based Biomarker Exploratory Study
NCT07030348 ·Status: RECRUITING
-
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
NCT04241367 ·Status: COMPLETED
-
The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.
NCT02406846 ·Status: COMPLETED
-
INTER-Regional COHORTE of Long Term Pancreatic Cancer Survivors
NCT04436679 ·Status: COMPLETED
-
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
NCT04246203 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer
NCT04616131 ·Status: UNKNOWN
-
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347 ·Status: WITHDRAWN
-
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147 ·Status: RECRUITING
-
Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable
NCT02818907 ·Status: COMPLETED ·Phase: NA
-
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
NCT04466189 ·Status: ENROLLING_BY_INVITATION
-
CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer
NCT04560270 ·Status: COMPLETED ·Phase: NA
-
CtDNA-guided Maintenance Therapy in Pancreatic Cancer
NCT07054879 ·Status: RECRUITING